Trial Profile
A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Trastuzumab emtansine
- Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jan 2023 Status changed from active, no longer recruiting to completed.
- 07 Nov 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2021.
- 07 Nov 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2020.